Sugi Predict

Sugi Predict / Compounds / SCHEMBL147587

SCHEMBL147587

SCHEMBL147587

Cc1c(Br)ccc(O)c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.46
▸ CA1 P00915 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA7 P43166 3/20 0.46
▸ CA9 Q16790 3/20 0.46
▸ CA14 Q9ULX7 3/20 0.46
▸ CYP3A4 P08684 2/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ LDHA P00338 2/20 0.37
▸ LDHB P07195 2/20 0.37
▸ THRB P10828 1/20 0.35
▸ MCL1 Q07820 2/20 0.35
▸ GPR35 Q9HC97 1/20 0.35
▸ EPRS1 P07814 1/20 0.35
▸ MAPT P10636 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ CA4 P22748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29684453 0.85 GPR35 (0.38) CA12CA1CA2CA7CA9
SCHEMBL28792146 0.85 GPR35 (0.38) CA12CA1CA2CA7CA9
SCHEMBL16334846 0.83 THRB (0.50) CA12CA1CA2CA7CA9
SCHEMBL6825576 0.83 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL1520727 0.82 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL29693892 0.81 TDP1 (0.39) CA12CA1CA2CA7CA9
SCHEMBL1085313 0.81 TDP1 (0.39) CA12CA1CA2CA7CA9
SCHEMBL1335275 0.79 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL6494516 0.78 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL31643882 0.78 CA12 (0.50) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119039272-A Compounds that modulate protein recruitment and/or degradation 奥里尼斯生物科学股份有限公司 2024-11-29 — — CN disclosed
CN-119039271-A Compounds that modulate protein recruitment and/or degradation 奥里尼斯生物科学股份有限公司 2024-11-29 — — CN disclosed
CN-119039273-A Compounds that modulate protein recruitment and/or degradation 奥里尼斯生物科学股份有限公司 2024-11-29 — — CN disclosed
CN-115038448-B Compounds that modulate protein recruitment and/or degradation 奥里尼斯生物科学股份有限公司 2024-09-10 — — CN disclosed
US-20230111853-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. 2023-04-13 — — US disclosed
EP-4076464-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION Orionis Biosciences, Inc. (US) 2022-10-26 — — EP disclosed
CN-115038448-A Compounds that modulate protein recruitment and/or degradation 奥里尼斯生物科学股份有限公司 2022-09-09 — — CN disclosed
WO-2021126973-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. (US) 2021-06-24 — — WO disclosed
WO-2021126973-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. (US) 2021-06-24 — — WO disclosed
CN-102325753-B Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL MYERS SQUIBB CO 2014-09-10 — — CN disclosed
EP-2391602-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-12-07 — — EP disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US disclosed
CN-101175720-A Novel haloalkyl sulfone substituted compounds useful for the treatment of obesity and diabetes NOVO NORDISK AS (DK) 2008-05-07 — — CN disclosed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 — — EP disclosed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 — — WO disclosed
EP-0967196-B1 Substituted 2-hydroxybenzophenones, preparation thereof, their use as fungicide and their fungicidal compositions BASF AG (DE) 2003-10-22 — — EP disclosed
US-6127570-A USEFUL AS FUNGICIDES HAVING HIGH SYSTEMICITIES AMERICAN CYANAMID COMPANY (US) 2000-10-03 — — US disclosed
EP-0967196-A2 Substituted 2-hydroxybenzophenones, preparation thereof, their use as fungicide and their fungicidal compositions American Cyanamid Company (US) 1999-12-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230111853-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION CRBN, STUB1, ADRM1 CA12 4120/4885CA1 3613/4885CA2 4399/4885
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES RPS12, GPR119, ATP12A CA12 1128/4885CA1 4202/4885CA2 1139/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 CA12 4437/4885CA1 3573/4885CA2 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.